Category

Press releases

Press releases

LUMICKS Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth

We are pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced…
Kassandra Barbetsea
17 August 2021
Press releases

First Center of Excellence on Dynamic Single-Molecule Studies for Brain and Disease Research Established in Belgium

We're proud to announce ithe installation of a C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy system at VIB, the life sciences research institute in Flanders, Belgium. The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.
Press releases

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi® Cell Avidity Analyzer

In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…
Press releases

LUMICKS Raises $93 Million in Series D Financing

Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors. Amsterdam, the Netherlands – April 16, 2021 – LUMICKS,…
Kassandra Barbetsea
15 April 2021
Press releases

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell…
Santiago Gisler
4 December 2020
Press releases

Introduction of LUMICKS consumables and script-sharing platform to facilitate faster, easier, and more reproducible Dynamic Single-Molecule analysis

In a move to broadly unlock Dynamic Single-Molecule (DSM) analysis, LUMICKS simultaneously launched two major initiatives: a new business line for reagents, biochemistry kits, and services, as well as its Harbor platform for sharing of DSM scripts. These new resources dramatically simplify the experimental workflow and make DSM analysis accessible…
Santiago Gisler
2 October 2020

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck